Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Benkert

Showing results (101-110 of 135) with videos related to

Pageof 14
Sort By:
JAMA Neurology|December 23, 2024
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum DisorderSu-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, et al.
Neurology|June 5, 2021
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple SclerosisPietro Maggi, Jens Kuhle, Sabine Schädelin, et al.
Brain : a Journal of Neurology|September 24, 2025
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosisRoberto Furlan, Sabine Schaedelin, Jette Lautrup Frederiksen, et al.
Plos One|April 1, 2016
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsGiulio Disanto, Pascal Benkert, Johannes Lorscheider, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Trials|September 11, 2024
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trialPerrine Janiaud, Chiara Zecca, Anke Salmen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Pageof 14

Showing results (101-110 of 135) with videos related to

Sort By:
Pageof 14
JAMA Neurology|December 23, 2024
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum DisorderSu-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, et al.
Neurology|June 5, 2021
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple SclerosisPietro Maggi, Jens Kuhle, Sabine Schädelin, et al.
Brain : a Journal of Neurology|September 24, 2025
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosisRoberto Furlan, Sabine Schaedelin, Jette Lautrup Frederiksen, et al.
Plos One|April 1, 2016
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsGiulio Disanto, Pascal Benkert, Johannes Lorscheider, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Trials|September 11, 2024
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trialPerrine Janiaud, Chiara Zecca, Anke Salmen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
The Lancet. Neurology|February 19, 2022
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyPascal Benkert, Stephanie Meier, Sabine Schaedelin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Pageof 14